Newborn Screening Services - Notice of Intent to Sole Source

Notice of Intent to Sole Source

The Naval Medical Logistics Command intends to award seven Single Award Task Order (SATO) Indefinite Delivery Indefinite Quantity (IDIQ), firm fixed priced sole source contracts under the authority of FAR 6.302-1 with the following state governments below as the only responsible source that can provide Newborn Screening for up to 63 conditions, Newborn Screening case management and Newborn Screening specialty physician consultation for positive diagnosed newborns.:

The government intends to make awards to the seven following states.  The Military Treatment Facilities (MTFs) serviced by each state’s laboratory/health department are listed below.

Genetic Disease Screening Program, California Department of Public Health

Naval Medical Center San Diego, CA; Naval Hospital Camp Pendleton, CA; Naval Hospital Twentynine Palms, CA

Newborn Screening Program, Florida Department of Health

Naval Hospital Jacksonville, FL; Naval Hospital Pensacola, FL; United States Naval Hospital Guantanamo Bay, Cuba

Newborn Screening Program, North Carolina Department of Health and Human Services

Naval Medical Center Camp Lejeune, NC

Newborn Screening Program, Virginia Department of General Services

Naval Medical Center Portsmouth, VA

Washington Newborn Screening Program, Washington State Department of Health

Naval Hospital Bremerton, WA; Naval Health Clinic Oak Harbor, WA

Newborn Screening Laboratory, Maryland Department of Health and Mental Hygiene

United States Naval Hospital Naples, Italy; United States Naval Hospital Sigonella, Italy; United States Naval Hospital Rota, Spain;

Northwest Regional Newborn Screening Program, Oregon State Public Health Laboratory

United States Naval Hospital Guam; United States Naval Hospital Yokosuka, Japan; United States Naval Hospital Okinawa, Japan

This acquisition is being conducted under FAR 6.302-1 only one source. Provisions and clauses in effect through Federal Acquisition Circular 2005-83 are incorporated.

Items being purchased in this acquisition:

The three requirements of the Navy’s Newborn Screening program are:

1. Newborn screen blood spot testing, to include at a minimum, the disorders in the Recommended Universal Screening Panel (RUSP).  The most up-to-date RUSP can be found here:
   http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/  
2. Newborn Screening case management system including processes for tracking cases and individuals whose role is to notify providers when an abnormal test result is identified, and to ensure and help coordinate appropriate follow-up care.
3. Newborn Screening specialty physician consultation (metabolic, endocrine, immunology and hematology), available as needed to communicate with providers to assist with newborn medical intervention and management.
    
   Newborn Screening is recognized nationally as an essential preventive public health measure established under Public Health Service Act, Title XI, § 1109 (42 U.S.C. 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) was originally put into place in 2008, was amended in 2014 and was recently amended and passed by the House of Representatives of the United States of America Congress on 24 July 2019.  Newborn screening is a well-established and proven health program that identifies newborns with certain genetic, metabolic, hormonal and functional conditions.  With the early detection afforded by Newborn Screening, affected infants receive prompt treatment, which can prevent permanent disability, developmental delay and even death.  A vital part of a successful screening program is appropriate medical intervention for positively tested babies.  For some of the disorders screened, this intervention may require urgent or even emergent medical care for the identified baby.  It is therefore critical to coordinate notification of abnormal results to healthcare providers to ensure appropriate intervention is initiated.  Newborn Screening testing is not just an endpoint, it is the gateway to state services for newborns. 

This acquisition is being conducted under the authority of FAR Part 6.302-1.  There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 621511 with a Small Business Size Standard of $35M.

This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement.  However, parties interested in responding to this notice shall submit technical data, including cost, sufficient to determine capability and experience in providing the same requirement.

Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point.  All capability statements received by closing of this notification of this synopsis will be considered by the government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response.

A determination by the government not to compete based on responses to this notice is solely within the discretion of the government.  Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Capability statements are due by 2:00 PM Local Time, April 29, 2020.  Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following addresses: cassandra.l.mahlstedt.civ@mail.mil and heather.m.skimson.civ@mail.mil.